This csv reports melanoma registration rates, per 100,000 population, by age. Age is grouped in 5 year segments (eg 0–4 years old, 5–9 years old). New Zealand and Australia have the world’s highest rates of melanoma, the most serious type of skin cancer. Melanoma is mainly caused by exposure to ultraviolet (UV) light, usually from the sun. New Zealand has naturally high UV levels, especially during summer.
The risk of developing melanoma is affected by factors such as skin colour and type, family history, and the amount of sun exposure. Melanoma can affect people at any age, but the chance of developing a melanoma increases with age. We report on age-standardised rates of melanoma to account for the increasing proportion of older people in our population. Our data on melanoma registrations come from the New Zealand Cancer Registry and the Ministry of Health's Mortality Collection. The passing of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 led to significant improvements in data quality and coverage (Ministry of Health, 2013). A sharp increase in registrations after 1993 is likely to have been related to these legislative and regulatory changes; for this reason we have only analysed data from 1996. 2014–15 data are provisional and subject to change. More information on this dataset and how it relates to our environmental reporting indicators and topics can be found in the attached data quality pdf.

Since 1988, individuals affected by melanoma in Southern Sweden has been interviewed and the cohort now consists of 3000 cases. For each case, two controls are randomly selected from the Skåne population registry and matched for sex, age and place of residence. The same questions have been sent also to the controls. These questions concern, among others, past illnesses, medication, exposure to UV light, alcohol, smoking, use of oral contraceptivesion and education. All patients with familial melanoma have been analyzed for a CDKN2A mutation. During 1995-96 blood was collected from all patients, but beyond that they have only blood collected from cases with familiar melanoma, cases aged under 40 and cases with multiple melanoma. The study is still ongoing.

Purpose:

The aim of the study is to create a cohort of patients with melanoma and controls to study risk factors for the disease.

Dataset includes the control group in the study.

Melanoma is the most severe type of skin cancer due to its ability to cause metastasis. It is more common in black people, often affecting acral regions: palms, soles, and nails. Deep neural networks have shown tremendous potential for improving clinical care and skin cancer diagnosis. Nevertheless, prevailing studies predominantly rely on datasets of white skin tones, neglecting to report diagnostic outcomes for diverse patient skin tones. In this work, we evaluate supervised and self-supervised models in skin lesion images extracted from acral regions commonly observed in black individuals. Also, we carefully curate a dataset containing skin lesions in acral regions and assess the datasets concerning the Fitzpatrick scale to verify performance on black skin. Our results expose the poor generalizability of these models, revealing their favorable performance for lesions on white skin. Neglecting to create diverse datasets, which necessitates the development of specialized models, is unacceptable. Deep neural networks have great potential to improve diagnosis, particularly for populations with limited access to dermatology. However, including black skin lesions is necessary to ensure these populations can access the benefits of inclusive technology.

New Zealand and Australia have the world’s highest rates of melanoma, the most serious type of skin cancer. Melanoma is mainly caused by exposure to ultraviolet (UV) light, usually from the sun. New Zealand has naturally high UV levels, especially during summer.
The risk of developing melanoma is affected by factors such as skin colour and type, family history, and the amount of sun exposure. Melanoma can affect people at any age, but the chance of developing a melanoma increases with age. We report on age-standardised rates of melanoma to account for the increasing proportion of older people in our population. Our data on melanoma registrations come from the New Zealand Cancer Registry and the Ministry of Health's Mortality Collection. The passing of the Cancer Registry Act 1993 and Cancer Registry Regulations 1994 led to significant improvements in data quality and coverage (Ministry of Health, 2013). A sharp increase in registrations after 1993 is likely to have been related to these legislative and regulatory changes; for this reason we have only analysed data from 1996. Trend direction was assessed using the Theil-Sen estimator and the Two One-Sided Test (TOST) for equivalence at the 95% confidence level. More information on this dataset and how it relates to our environmental reporting indicators and topics can be found in the attached data quality pdf.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

This dataset presents the footprint of cancer incidence statistics in Australia for all cancers combined and the 6 top cancer groupings (colorectal, leukaemia, lung, lymphoma, melanoma of the skin and pancreas) and their respective ICD-10 codes. The data spans the years 2006-2010 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS).

Incidence data refer to the number of new cases of cancer diagnosed in a given time period. It does not refer to the number of people newly diagnosed (because one person can be diagnosed with more than one cancer in a year). Cancer incidence data come from the Australian Institute of Health and Welfare (AIHW) 2012 Australian Cancer Database (ACD).

For further information about this dataset, please visit:

• Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books.

• Australian Cancer Database 2012 Data Quality Statement.

Please note:

• AURIN has spatially enabled the original data using the Department of Health - PHN Areas.

• Due to changes in geographic classifications over time, long-term trends are not available.

• Values assigned to "n.p." in the original data have been removed from the data.

• The Australian and jurisdictional totals include people who could not be assigned a PHN. The number of people who could not be assigned a PHN is less than 1% of the total.

• The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory).

• The ACD records all primary cancers except for basal and squamous cell carcinomas of the skin (BCCs and SCCs). These cancers are not notifiable diseases and are not collected by the state and territory cancer registries.

• The diseases coded to ICD-10 codes D45-D46, D47.1 and D47.3-D47.5, which cover most of the myelodysplastic and myeloproliferative cancers, were not considered cancer at the time the ICD-10 was first published and were not routinely registered by all Australian cancer registries. The ACD contains all cases of these cancers which were diagnosed from 1982 onwards and which have been registered but the collection is not considered complete until 2003 onwards.

• Note that the incidence data presented are for 2006-2010 because 2011 and 2012 data for NSW and ACT were not able to be provided for the 2012 ACD.

Context

These are images re-sliced from SIIM-ISIC-Melanoma Classification competition

Content

This competition offers very fine grained image, it's a shame we have to all of them into less than 512x512 to put it into the model. And in some common sense, the texture and pattern of the such detail really should matter.

Acknowledgements

The image id from train and test dataset match exactly with the original dataset from the competition

Inspiration

Sorry for sharing this too late.

During the competition, I try my pytorch-lightning notebook onto this dataset 3 days before the final submission, and the public LB score hasn't seen improvements(around .91 for 5 folds efficientnet-b5 x4tta ). Maybe I did it wrong. Or maybe I should combine this with other normally resized datasets

IntroductionMelanoma, a highly aggressive form of skin cancer, and Parkinson’s disease (PD), a progressive neurodegenerative disorder, have been epidemiologically linked, showing a positive association that suggests a shared etiology. This association implies that individuals with one condition may have an increased risk of developing the other. However, the specific molecular mechanisms underlying this relationship remain unclear. This study aimed to elucidate the molecular mechanisms by conducting a comprehensive comparative analysis of gene expression profiles in both PD and melanoma to identify common differentially expressed genes (DEGs) that may contribute to the pathophysiological overlap between these two conditions.MethodsWe analyzed two independent publicly available genomic datasets to identify overlapping DEGs associated with both PD and melanoma. Regulatory networks, including transcription factors (TFs), DEGs, and microRNAs (miRNAs), were constructed. Protein-protein interaction (PPI) networks were established to identify hub genes. Additionally, we investigated the interplay between PD, melanoma, and immune cell infiltration to uncover potential correlations between the expression levels of hub genes and specific subsets of immune cells. Molecular docking studies were performed to identify potential therapeutic agents targeting the DEGs.ResultsA total of 41 overlapping DEGs were identified, including VSNL1, ATP6V1G2, and DNM1, which were significantly down-regulated in both PD and melanoma patients. These genes play critical roles in biological processes, cellular components, and molecular functions relevant to the pathogenesis of both diseases. VSNL1 is associated with synaptic vesicle fusion and may impact neuronal communication compromised in PD. ATP6V1G2, a subunit of the V-ATPase, is involved in the dysregulated pH homeostasis observed in melanoma. DNM1, a key player in vesicle trafficking, may influence aberrant cellular transport processes in both diseases. Regulatory and PPI networks revealed potential hub genes and their interactions. Molecular docking studies identified retinoic acid as a potential therapeutic agent targeting VSNL1, ATP6V1G2, and DNM1.DiscussionOur study provides insights into the shared molecular characteristics of PD and melanoma, identifying potential biomarkers for early diagnosis and prognosis and revealing new therapeutic targets. The discovery of retinoic acid as a promising therapeutic agent represents a significant step forward in drug development and treatment strategies for these diseases. This comprehensive analysis enhances our understanding of the intricate molecular mechanisms underlying the association between PD and melanoma, paving the way for further research and therapeutic advancements. The findings hold the promise of improved diagnosis, prognosis, and personalized treatment strategies for individuals affected by these debilitating diseases.

This dataset presents the footprint of cancer incidence statistics in Australia for all cancers combined and the 5 top cancer groupings (breast - female only, colorectal, lung, melanoma of the skin and prostate) and their respective ICD-10 codes. The data spans the years 2006-2010 and is aggregated to Statistical Area Level 3 (SA3) from the 2011 Australian Statistical Geography Standard (ASGS). Incidence data refer to the number of new cases of cancer diagnosed in a given time period. It does not refer to the number of people newly diagnosed (because one person can be diagnosed with more than one cancer in a year). Cancer incidence data come from the Australian Institute of Health and Welfare (AIHW) 2012 Australian Cancer Database (ACD).

This dataset presents the footprint of cancer mortality statistics in Australia for all cancers combined and the 6 top cancer groupings (colorectal, leukaemia, lung, lymphoma, melanoma of the skin …Show full descriptionThis dataset presents the footprint of cancer mortality statistics in Australia for all cancers combined and the 6 top cancer groupings (colorectal, leukaemia, lung, lymphoma, melanoma of the skin and pancreas) and their respective ICD-10 codes. The data spans the years 2009-2013 and is aggregated to Statistical Area Level 4 (SA4) from the 2011 Australian Statistical Geography Standard (ASGS). Mortality data refer to the number of deaths due to cancer in a given time period. Cancer deaths data are sourced from the Australian Institute of Health and Welfare (AIHW) 2013 National Mortality Database (NMD). For further information about this dataset, please visit: Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books. Australian Institute of Health and Welfare - 2013 National Mortality Database. Please note: AURIN has spatially enabled the original data. Due to changes in geographic classifications over time, long-term trends are not available. Values assigned to "n.p." in the original data have been removed from the data. The Australian and jurisdictional totals include people who could not be assigned a SA4. The number of people who could not be assigned a SA4 is less than 1% of the total. The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory). Cause of Death Unit Record File data are provided to the AIHW by the Registries of Births, Deaths and Marriages and the National Coronial Information System (managed by the Victorian Department of Justice) and include cause of death coded by the Australian Bureau of Statistics (ABS). The data are maintained by the AIHW in the NMD. Year refers to year of occurrence of death for years up to and including 2012, and year of registration of death for 2013. Deaths registered in 2011 and earlier are based on the final version of cause of death data; deaths registered in 2012 and 2013 are based on revised and preliminary versions, respectively and are subject to further revision by the ABS. Cause of death information are based on underlying cause of death and are classified according to the International Classification of Diseases and Related Health Problems (ICD). Deaths registered in 1997 onwards are classified according to the 10th revision (ICD-10). Colorectal deaths presented are underestimates. For further information, refer to "Complexities in the measurement of bowel cancer in Australia" in Causes of Death, Australia (ABS cat. no. 3303.0). Copyright attribution: Government of the Commonwealth of Australia - Australian Institute of Health and Welfare, (2016): ; accessed from AURIN on 12/3/2020. Licence type: Creative Commons Attribution 3.0 Australia (CC BY 3.0 AU)

Abstract copyright UK Data Service and data collection copyright owner.The Opinions and Lifestyle Survey (formerly known as the ONS Opinions Survey or Omnibus) is an omnibus survey that began in 1990, collecting data on a range of subjects commissioned by both the ONS internally and external clients (limited to other government departments, charities, non-profit organisations and academia).Data are collected from one individual aged 16 or over, selected from each sampled private household. Personal data include data on the individual, their family, address, household, income and education, plus responses and opinions on a variety of subjects within commissioned modules. The questionnaire collects timely data for research and policy analysis evaluation on the social impacts of recent topics of national importance, such as the coronavirus (COVID-19) pandemic and the cost of living, on individuals and households in Great Britain. From April 2018 to November 2019, the design of the OPN changed from face-to-face to a mixed-mode design (online first with telephone interviewing where necessary). Mixed-mode collection allows respondents to complete the survey more flexibly and provides a more cost-effective service for customers. In March 2020, the OPN was adapted to become a weekly survey used to collect data on the social impacts of the coronavirus (COVID-19) pandemic on the lives of people of Great Britain. These data are held in the Secure Access study, SN 8635, ONS Opinions and Lifestyle Survey, Covid-19 Module, 2020-2022: Secure Access. From August 2021, as coronavirus (COVID-19) restrictions were lifting across Great Britain, the OPN moved to fortnightly data collection, sampling around 5,000 households in each survey wave to ensure the survey remains sustainable. The OPN has since expanded to include questions on other topics of national importance, such as health and the cost of living. For more information about the survey and its methodology, see the ONS OPN Quality and Methodology Information webpage.Secure Access Opinions and Lifestyle Survey dataOther Secure Access OPN data cover modules run at various points from 1997-2019, on Census religion (SN 8078), cervical cancer screening (SN 8080), contact after separation (SN 8089), contraception (SN 8095), disability (SNs 8680 and 8096), general lifestyle (SN 8092), illness and activity (SN 8094), and non-resident parental contact (SN 8093). See Opinions and Lifestyle Survey: Secure Access for details. Main Topics:Each month's questionnaire consists of two elements: core questions, covering demographic information, are asked each month together with non-core questions that vary from month to month. The non-core questions for this month were: Company Cars (Module 1a): questions about the number of petrol-fuelled and diesel-fuelled company cars as well as total mileage and total business mileage. Also questions are asked on age, engine size and value of car when new. Melanoma (Modules 49a and 49b): knowledge of the term Melanoma and about the main signs of and ways to avoid the disease. Also comparing knowledge in leaflet- campaign districts with that in the rest of the country. Sunday Working (Module 52): questions about current Sunday working and whether shopping and other activities done on Sundays. A sample of people's employers will also be followed up by telephone and asked about their use of Sunday working. Organ Transplants (Module 53): questions asking for views on various aspects of organ donation for transplant operations - carrying donor cards, agreeing to donate the person's own organ or a relative's organ and accepting an organ transplant. Fire Safety (Module 33): a before-and-after study of the effects of Fire Safety Week which takes place in October 1992. Awareness of Fire Safety Week, knowledge of facts about fire safety and precautions taken. Second Homes (Module 4): ownership of a second home by any member of the household and reasons for having the second home. Multi-stage stratified random sample Face-to-face interview

This dataset presents the footprint of male cancer mortality statistics in Australia for all cancers combined and the 11 top cancer groupings (bladder, colorectal, head and neck, kidney, leukaemia, lung, lymphoma, melanoma of the skin, pancreas, prostate and stomach) and their respective ICD-10 codes. The data spans the years 2009-2013 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS). Mortality …Show full descriptionThis dataset presents the footprint of male cancer mortality statistics in Australia for all cancers combined and the 11 top cancer groupings (bladder, colorectal, head and neck, kidney, leukaemia, lung, lymphoma, melanoma of the skin, pancreas, prostate and stomach) and their respective ICD-10 codes. The data spans the years 2009-2013 and is aggregated to 2015 Department of Health Primary Health Network (PHN) areas, based on the 2011 Australian Statistical Geography Standard (ASGS). Mortality data refer to the number of deaths due to cancer in a given time period. Cancer deaths data are sourced from the Australian Institute of Health and Welfare (AIHW) 2013 National Mortality Database (NMD). For further information about this dataset, please visit: Australian Institute of Health and Welfare - Cancer Incidence and Mortality Across Regions (CIMAR) books. Australian Institute of Health and Welfare - 2013 National Mortality Database. Please note: AURIN has spatially enabled the original data using the Department of Health - PHN Areas. Due to changes in geographic classifications over time, long-term trends are not available. Values assigned to "n.p." in the original data have been removed from the data. The Australian and jurisdictional totals include people who could not be assigned a PHN. The number of people who could not be assigned a PHN is less than 1% of the total. The Australian total also includes residents of Other Territories (Cocos (Keeling) Islands, Christmas Island and Jervis Bay Territory). Cause of Death Unit Record File data are provided to the AIHW by the Registries of Births, Deaths and Marriages and the National Coronial Information System (managed by the Victorian Department of Justice) and include cause of death coded by the Australian Bureau of Statistics (ABS). The data are maintained by the AIHW in the NMD. Year refers to year of occurrence of death for years up to and including 2012, and year of registration of death for 2013. Deaths registered in 2011 and earlier are based on the final version of cause of death data; deaths registered in 2012 and 2013 are based on revised and preliminary versions, respectively and are subject to further revision by the ABS. Cause of death information are based on underlying cause of death and are classified according to the International Classification of Diseases and Related Health Problems (ICD). Deaths registered in 1997 onwards are classified according to the 10th revision (ICD-10). Colorectal deaths presented are underestimates. For further information, refer to "Complexities in the measurement of bowel cancer in Australia" in Causes of Death, Australia (ABS cat. no. 3303.0). Copyright attribution: Government of the Commonwealth of Australia - Australian Institute of Health and Welfare, (2016): ; accessed from AURIN on 12/3/2020. Licence type: Creative Commons Attribution 3.0 Australia (CC BY 3.0 AU)

The dataset contains information of 213 cancer patients undergoing clinical or surgical treatment characterized on sociodemographic and clinical data as well as data from the Care Transition Measure (CTM 15-Brazil). Data collection was carried out 7 to 30 days after their discharge from hospital from June to August 2019. Understanding these data can contribute to improving quality of care transitions and avoiding hospital readmissions. To this end, this dataset contains a broad array of variables:

*gender

*age group

*place of residence

*race

*marital status

*schooling

*paid work activity

*type of treatment

*cancer staging

*metastasis

*comorbidities

*main complaint

*continue use medication

*diagnosis

*cancer type

*diagnostic year

*oncology treatment

*first hospitalization

*readmission in the last 30 days

*number of hospitalizations in the last 30 days

*readmission in the last 6 months

*number of hospitalizations in the last 6 months

*readmission in the last year

*number of hospitalizations in the last year

*questions 1-15 from CTM 15-Brazil

The data are presented as a single Excel XLSX file: cancer patient´s care transitions dataset.xlsx.

The analyses of the present dataset have the potential to generate hospital readmission prevention strategies to be implemented by the hospital team. Researchers who are interested in CTs of cancer patients can extensively explore the variables described here.

The project from which these data were extracted was approved by the institution’s research ethics committee (approval n. 3.266.259/2019) at Associação Hospital de Caridade Ijuí, Rio Grande do Sul, Brazil.

List of relevant studies using DL and ML algorithms for skin cancer identification.

The Welsh Cancer Intelligence & Surveillance Unit (WCISU) is the National Cancer Registry for Wales and its primary role is to record, store and report on all incidence of cancer for the resident population of Wales wherever they are treated. Cancer registration in Wales began almost five decades ago and today’s electronic database which holds records going back to 1972 contains in the region of 686,000 records.

WCISU collects data about occurrences of cancer in Welsh residents via direct or indirect submissions from Welsh Hospitals.

Staging of malignant melanoma (ICD 10 code C43), breast (C50), colorectal (C18-C20) and cervix (C53) started in 2001 since this was when we started receiving pathological information. Staging for all other cancers started in 2010.

Treatment information started in 1995.

Abstract copyright UK Data Service and data collection copyright owner.

The Health Survey Northern Ireland (HSNI) was commissioned by the Department of Health in Northern Ireland and the Central Survey Unit (CSU) of the Northern Ireland Statistics and Research Agency (NISRA) carried out the survey on their behalf. This survey series has been running on a continuous basis since April 2010 with separate modules for different policy areas included in different financial years. It covers a range of health topics that are important to the lives of people in Northern Ireland. The HSNI replaces the previous Northern Ireland Health and Social Wellbeing Survey (available under SNs 4589, 4590 and 5710).

Adult BMI, height and weight measurements, accompanying demographic and derived variables, geography, and a BMI weighting variable, are available in separate datasets for each survey year.

Further information is available from the Northern Ireland Statistics and Research Agency and the Department of Health (Northern Ireland) survey webpages.